[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637759":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":32,"locations":44,"responsibleParty":58,"collaborators":10,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":10,"enrollmentInfo":71,"targetDuration":10,"studyType":74,"phases":10,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":46,"whyStopped":10,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Hospital Italiano de Buenos Aires","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with Type 2 Diabetes Treated with Semaglutide (Oral or Subcutaneous)",null,"This cohort includes adults aged 18 years or older with type 2 diabetes mellitus who initiate treatment with oral or subcutaneous semaglutide as prescribed by their treating physician in routine clinical practice. The study is observational and does not assign treatment. Dose, formulation, and route of administration are determined by the treating physician according to standard care.",[13],"Drug: semaglutide",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","semaglutide","Participants will receive semaglutide as part of their usual medical care for type 2 diabetes mellitus. The intervention of interest includes both oral and subcutaneous formulations of semaglutide, prescribed and dosed at the discretion of the treating physician according to routine clinical practice.",[9],[21,25,28],{"name":22,"affiliation":23,"role":24},"María Natalia Nachón, MD","Hospital General de Agudos Dr Enrique Tornú","PRINCIPAL_INVESTIGATOR",{"name":26,"affiliation":5,"role":27},"Iván A Huespe, MD","STUDY_DIRECTOR",{"name":29,"affiliation":30,"role":31},"Matías Mirofsky, MD","Hospital Leónidas Lucero, Bahía Blanca","STUDY_CHAIR",[33,39],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":38},"Martín L Gil Folgar, MD","CONTACT","1520497361","+5411","martin.gilfolgar@hospitalitaliano.org.ar",{"name":40,"role":35,"phone":41,"phoneExt":42,"email":43},"Natalia Nachón, MD","155876-3407","+54 9 11","dra.nachon@gmail.com",[45,53],{"facility":5,"status":46,"city":47,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":10,"geoPoint":10,"contacts":51},"RECRUITING","Buenos Aires","1199","Argentina","AR",[52],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":38},{"facility":23,"status":46,"city":47,"state":47,"zip":54,"country":49,"countryCode":50,"cosmosGeoPoint":10,"geoPoint":10,"contacts":55},"1427",[56],{"name":57,"role":35,"phone":41,"phoneExt":42,"email":43},"María N Nachón, MD",{"type":24,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Ivan A. Huespe","Head of Research ICU","100637759","study-of-adult-patients-residing-in-argentina-diagnosed-with-type-2-diabetes-treated-with-a-new-formulation-of-semaglutide-both-oral-and-subcutaneous-in-a-real-world-setting-at-3-months-6-months-and-1-year-of-follow-up-quantifying-the-reduction-in-glycated-hemoglobin-100637759",false,"NCT07621419","Study of Adult Patients Residing in Argentina Diagnosed With Type 2 Diabetes Treated With a New Formulation of Semaglutide, Both Oral and Subcutaneous, in a Real-world Setting at 3 Months, 6 Months, and 1 Year of Follow-up, Quantifying the Reduction in Glycated Hemoglobin","New Formulation of Semaglutide in the Treatment of Type 2 Diabetes in Argentina: a Prospective, Multicenter, Real-world Study","SEMA-REAL ARG","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Clinical diagnosis of type 2 diabetes mellitus.\n* Baseline glycated hemoglobin (HbA1c) \\>7% and ≤12%.\n* Initiating treatment with semaglutide (oral or subcutaneous) prescribed by the treating physician according to clinical judgment.\n\nExclusion Criteria:\n\n* Pregnancy or lactation at the time of enrollment.\n* History of severe hypersensitivity or adverse reactions to glucagon-like peptide-1 (GLP-1) receptor agonists.\n* Contraindications to semaglutide as listed in the product label (e.g., severe gastrointestinal disease, certain endocrine tumors).\n* Any other serious medical condition that, in the investigator's opinion, may interfere with study participation or data interpretation.","ALL","18 Years",{"count":72,"type":73},145,"ESTIMATED","OBSERVATIONAL","The goal of this prospective, multicenter, observational study is to evaluate the real-world effectiveness and safety of oral and subcutaneous semaglutide in adults with type 2 diabetes mellitus in Argentina. The main objective is to assess changes in glycated hemoglobin (HbA1c) from baseline to 3, 6, and 12 months after treatment initiation. Secondary objectives include evaluating changes in body weight, waist circumference, hand-grip strength, treatment satisfaction, medication adherence, treatment route switching, treatment discontinuation, and adverse events.\n\nParticipants will receive semaglutide as prescribed by their treating physician as part of routine clinical care. Follow-up assessments will be performed at 3, 6, and 12 months to collect clinical, laboratory, safety, treatment satisfaction, and adherence data. Treatment satisfaction will be assessed using the Diabetes Treatment Satisfaction Questionnaire (DTSQ), and adherence will be assessed using the Simplified Medication Adherence Questionnaire (SMAQ).",[77],"Diabetes Mellitus",[17,79,80,81,82],"real world study","obesity","type II diabetes","Argentinian Society of Medicine","2026-06-01",{"date":85,"type":86},"2026-06-02","ACTUAL",{"date":88,"type":86},"2025-08-04",{"date":90,"type":73},"2028-12-31",{"name":5,"class":6},2]